A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

NCT07724106 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
mRNA Vaccine

Interventions

DRUG: Low Dose
DRUG: middle dose
DRUG: high dose

Sponsor

West China Hospital